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Objective: To investigate whether smoking and other cardiovascular risk factors were associated with deterioration of 
ankle/brachial pressure index or onset of critical ischaemia in patients with mild to moderate intermittent claudication 
Design and setting: Longitudinal study in a London teaching hospital. 
Subjects: 415 consecutive smokers, with symptoms of intermittent claudication and an ankle/brachial pressure index of 
< 0.9, referred for a surgical opinion between April 1985 and December 1990, who were not considered for an immediate 
surgical procedure. 
Main outcome results: Reduction in ankle/brachiaI pressure index of > 0.14, onset of critical limb ischaemia. 
Results: After one year of follow up 183 patients (44%) patients had stopped smoking (as evaluated by biochemical 
markers). With longer follow up only 110 patients (27%) had maintained smoking cessation. There were no differences in 
age, sex, and previous tobacco exposure between stoppers and smokers, but the proportion of diabetics among stoppers 
(20%) was greater than among those who continued smoking (10%) [p = 0.011. The annual rate of deterioration of ABPI 
was 21, 16 and 17% respectively in the first, second and third year of follow-up and the onset of critical ischaemia was 
observed in 52 patients (12.5%) during the period of follow-up. In univariate analyses, continued smoking, diabetes and 
presence of ischaemic heart disease were not associated with an increased risk of deterioration of ABPI, but 
hypertriglyceridaemia ( ~2.2 mmoI/l) was, [relative risk 1.7(95% CI 1.21-2.37), p = 0.003], and patients having systolic 
blood pressure in the middle tertile (153-170 mmHg had a reduced risk of deterioration of ABPL p=0.026. 
Hypertriglyceridaemia (>-2.2mmol/l) was the only independent factor associated with deterioration of ABPI in 
multivariate analysis [relative risk 1.8(95% Chl.23-2.59), p = 0.003] and also was associated with a relative risk of onset 
of critical ischaemia of 1.9 [(95% Ch 1.08-2.87), p = 0.035], compared with triglyceride levels of < 2.2mmoI/l. 
Conclusion: For those with mild to moderate claudication, the lack of immediate benefit from cessation of smoking appears 
to be associated with a gradual return to smoking..Hypertriglyceridaemia wasidentified as the most important independent 
factor associated with the progression of peripheral arterial disease and onset of critical ischaemia. 
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Introduction 
Intermittent claudication is a common condition, 
which impairs quality of life in the ageing population. 
Intermittent claudication is one manifestation of gen- 
eralised atherosclerosis, smoking being a particularly 
potent risk factor. ~-3 Several studies have addressed 
the natural history of intermittent claudication. Over 
30 years ago a Danish study suggested smoking did 
not predict outcome effectively among patients with 
peripheral arterial disease. 4 Later a study from Oxford 
indicated that cessation of smoking was associated 
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with an improved outcome for patients with inter- 
mittent claudication, but the small size of the study 
necessitated cumulating adverse events, including 
vascular surgery, stroke and death, to demonstrate his 
effect. 5 A larger Swedish study of 343 patients with 
intermittent claudication, indicated that cessation of 
smoking diminished the risk of critical eg ischaemia. 6 
These studies provide the basis for the first half of the 
often quoted treatment for intermittent claudication 
"stop smoking and keep walking". 7 Other studies 
have demonstrated a poorer prognosis for intermittent 
claudication where the presenting ankie/brachial 
pressure index was < 0.5, but failed to comment about 
the influence of smoking. 8'9 Our own experience has 
shown that many patients with peripheral arterial 
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disease are "economical with the truth" about their 
smoking habit and objective markers of smoking are 
often necessary to identify those who continue to 
smoke. 10'11 Therefore, in 1985, we established a longi- 
tudinal study of patients with mild to moderate 
claudication to investigate whether objectively eval- 
uated cessation of smoking and other recognised risk 
factors for peripheral arterial disease (diabetes, hyper- 
tension, ischaemic heart disease and dyslipidaemia) 
would affect progression of peripheral arterial disease 
in these patients as measured by changes in ankle/ 
brachial systolic pressure index and the onset of 
critical ischaemia. 
Patients and Methods 
The patients included consecutive smokers, as con- 
firmed by a whole blood carboxyhaemoglobin co cen- 
tration of > 2.0% and/or a plasma cotinine concentra- 
tion of >200 mmol/1, who were referred to the 
Regional Vascular Service at Charing Cross Hospital 
between April 1985 and December 1990 for a surgical 
opinion of their peripheral arterial symptoms. The 
diagnosis of peripheral arterial disease was estab- 
lished by the presence of an ankle/brachial systolic 
pressure index (ABPI) of < 0.9. A total of 551 smokers 
with peripheral arterial disease were recruited uring 
this period and were advised strongly never to smoke 
again. Of these, 136 (25%) underwent a revasculariza- 
tion procedure within one month of referral and were 
excluded from the follow-up study. The 415 patients 
entering the follow up study had a median age of 65 
years, 249 (60%) male, and returned to clinic at 3 
months and then at biannual or annual intervals. 
Follow up continued until April 1992. Over the period 
of the study 106 patients (26%) died and 120 (29%) 
were lost to follow-up. 
On entering the study, a medical and smoking 
history was taken, height, weight and blood pressure 
measured in addition to ABPI in both legs, a resting 
ECG recorded, and a fasting blood sample taken for 
the measurement of cholesterol, triglyceride and 
glucose concentrations. At follow up ABPI was meas- 
ured in both legs, patients were questioned about heir 
smoking habit and a blood sample taken for the 
estimation of carboxyhaemoglobin, cotinine and glu- 
cose concentrations. The resting ECG was coded by 
two independent observers using the Minnesota clas- 
sification. 12 Carboxyhaemoglobin a d cotinine were 
measured as described previously. 11"~3 Patients were 
classified as having stopped smoking (stopper) if 
carboxyhaemoglobin a d/or cotinine concentrations 
were in the non-smoking range at more than 75% of 
the follow up visits. Progression of peripheral arterial 
disease was assessed from a reduction in ABPI of 
> 0.14 and the onset of critical ischaemia. ~4'~5 
Non parametric analysis was used to compare 
presenting variables, using Mann Whitney or chi- 
squared tests as appropriate. The values given in the 
tables are median (interquartile range). For continuous 
variables (ABPI, age, BMI, cholesterol, triglycerides, 
pack-years of smoking) patients were categorized into 
tertiles. The comparison of risk factors was made by 
calculating the relative risk and comparing the results 
using Chi-squared tests (uncorrected). Where more 
than two categories were present for a variable, Chi- 
squared for trend was also calculated. Analysis for 
progression of disease was up to the time of a decrease 
in ABPI from value at presentation of > 0.14 in either 
leg. 12 Life table analysis, with calculation of sig- 
nificance using the log-rank method was used for 
disease progression. The Cox proportional hazard 
model was used to adjust he data for diabetes and for 
stepwise backward multiple regression analysis. 
Results 
Smokers and stoppers 
At the first follow-up visit (approximately 3 months 
after the initial consultation) 183 of the 415 patients 
(44%) had biochemical markers compatible with stop- 
ping smoking (carboxyhaemoglobin of < 2.0% and/or 
a plasma cotinine concentration of <200 nmol/1). 
With longer surveillance (mean time 12-18 months), 
73 of these 183 patients had carboxyhaemoglobin 
and/or cotinine concentrations which had returned to 
the smoking range. Only 110 patients (27%) could be 
classified as stoppers, the majority of these (84/110, 
76%) were recruited towards the end of the study in 
the period 1988-1990. Therefore the median follow-up 
for the stoppers, 18 months, was significantly less than 
the median follow-up, 31 months, for the 305 continu- 
ing or intermittent smokers. The smokers (including 
those who stopped transiently) and the stoppers were 
well matched for age, sex, previous history of tobacco 
exposure and ABPI (Table 1). More diabetics were 
found among stoppers [22/110 (20%)] than among 
smokers [30/305 (10%) p=0.01] (Table 1). Stoppers 
also had higher systolic blood pressure and serum 
cholesterol than smokers, but these differences were 
not statistically significant (Table 1). 
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Deterioration ofankle/brachiat pressure index (ABPI) 
During follow up, 83 patients (21%) had a reduction in 
ABPI in one or both legs of > 0.14 in the first year, 45 
patients (16%) in the second year, 25 patients (17%) in 
Table 1. Presenting characteristics of patients according to smoking 
status 
Smokers Stoppers p 
Age (years) 64.8 (58.3-71.2) 65.5 (58.8-73.3) 0.235 
Males (%) 186 (61%) 63 (57%) 0.570 
BMI (kg/m 2) 25.2 (22.7-27.4) 25.0 (22.0-27.6) 0.704 
Diabetes (%) 30 (10%) 22 (20%) 0.010 
Smoking (pack years) 41 (25-58) 40 (28-62) 0.332 
Ischaemic hanges on ECG 
None 63% 66% 0.658 
Possible 29% 24% 
Definite 8% 10% 
Systolic blood pressure 160 (1.60-1.71) 166 (1.60-1.72) 0.158 
(mmHg) 
Serum cholesterol 6.5 (5.8-7.6) 6.8 (5.9-7.7) 0.196 
(mmol/1) 
Serum triglycerides 1.6 (1.2-2.2) 1.6 (1.0-2.2) 0.507 
(retool/l) 
ABPI 0.57 (0.45-0.68) 0.56 (0.45-0.68) 0.878 
Smoking status was determined from the smoking markers 
carboxyhaemoglobin and cotinine. Results for continuous variables 
are given as median (interquartile range). 
the third year and in a further 12 patients after 3 years, 
shown by life table in Fig. 1. The relative risks of 
deterioration of ABPI, unadjusted and adjusted for 
diabetes, according to presenting characteristics are 
shown in Table 2. The unadjusted relative risk 
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Fig. 1. The progression ofperipheral arterial disease in smokers. The 
cumulative survival of 415 patients with intermittent claudication, 
who smoked at the time of diagnosis, according to the deterioration 
of ABPI or the onset of critical ischaemia. The numbers in 
parentheses show the patients entering each time interval. (©) 
critical ischaemia; (IH) ABPI deterioration. 
Table 2. Factors associated with the deterioration of ABPI 
RR adjusted 
n Unadjusted RR 95% CI p for diabetes 95% CI p 
Age (years) <60.7 138 1.0 1.0 
60.7~3.1 140 1.36 (0.94-1.96) 1.36 (0.94-1.96) 
>63.2 137 0.95 (0.77-1.16) 0.638 0.93 (0.77-1.16) 0.641 
Sex Male 249 1.0 1.0 
Female 166 1.2 (0.87-1.64) 0.260 1.20 (0.61-1.15) 0.259 
BMI (kg/m 2) <23.3 138 1.0 1.0 
23.3-26.5 137 0.89 (0.58-1.35) 0.89 (0.58-1.35) 
>26.6 140 0.95 (0.77-1.18) 0.641 0.95 (0.77-1.17) 0.662 
Diabetes No 363 1.0 
Yes 52 1.07 (0.67-1.70) 0.788 
Smoking Stopped 305 1.0 1.0 
Smoker 110 0.78 (0.54-1.13) 0.195 0.79 (0.58-1.24) 0.207 
Pack years of <30 136 1.0 1.0 
smoking 3049 134 1.32 (0.87-2.02) 1.34 (0.87-2.06) 
>50 132 1.05 (0.85-1.29) 0.663 1.05 (0.88-1.25) 0.659 
Ischaemic hanges None 209 1.0 1.0 
on ECG Possible 90 1.43 (0.99-2.08) 1.44 (0.99-2.08) 
Definite 29 0.93 (0.67-1.30) 0.468 0.93 (0.66-1.30) 0.476 
Systolic blood <150 138 1.0 1.0 
pressure (mmHg) 150-173 134 0.52 (0.35-0.78) 0.53 (0.35-0.78) 
>173 133 0.89 (0.74-1.07) 0.183 0.90 (0.75-1.08) 0.188 
ABPI >0.64 138 1.0 1.0 
0.5-0.63 140 1.18 (0.67-2.13) 1.18 (0.67-2.13) 
<0.5 137 1.18 (0.97-1.44) 0.080 1.18 (0.97-1.44) 0.081 
Cholesterol <6.0 135 1.0 1.0 
mmol/1 6.0-7.1 134 0.96 (0.64-1.48) 1.44 (0.98-2.08) 
>7.2 133 0.97 (0.80-1.17) 0.744 0.93 (0.66-1.30) 0.746 
Triglycerides <2.2 273 1.0 1.0 
mmol/L >2.2 108 1.69 (1.21-2.37) 0.003 1.72 (1.22-2.43) 0.022 
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triglyceride concentration of > 2.2 mmol/1 (p = 0.003), 
and remained similarly increased after adjustment for 
diabetes (p = 0.022). The ABPI for patients with tri- 
glyceride concentrations of >2.2 mmol/1, [median 
0.59 (0.49-0.67)] at baseline was similar to that in 
patients with lower triglyceride concentrations 
[median 0.56 (0.45-0.66)]. Life table analysis also 
showed that patients with hypertriglyceridaemia had 
a significantly increased rate of deterioration of ABPI, 
p = 0.022 (Fig. 2). Patients presenting with an ABPI of 
< 0.5 had an increased risk of deterioration of ABPI 
but, even after adjustment for diabetes where incom- 
pressible arteries may give falsely elevated ankle 
pressures, this failed to achieve significance, p = 0.096. 
Patients who had stopped smoking did not have a 
reduced risk of deterioration of ABPI and neither was 
the highest level of previous tobacco exposure asso- 
ciated with risk of disease progression. The presence 
of ischaemic heart disease, whether discerned from 
self-reported history or the resting ECG, was not 
associated with an increased risk of deterioration of 
ABPI. Patients in the middle tertile for systolic blood 
pressure (150-175 mm Hg) were at some reduced risk 
of deterioration ofABPI. Life table analysis hows that 
these patients had a significant reduction in the rate of 
deterioration of ABPI, p = 0.026, in comparison with 
the lower and upper tertiles (Fig. 3). However, there 
was a significant linear inverse association between 
presenting systolic pressure and ABPI (of which 
systolic pressure is a component) [p = 0.01, (Kruskal- 
Wallis)]. 
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Fig. 2. Triglyceride concentration a d the progression of peripheral 
arterial disease. Progression of peripheral arterial disease has been 
assessed by reduction in ankle/brachial systolic pressure index 
(ABPI). The number of patients entering each time interval is shown 
in parentheses. Data is shown for only 376/415 patients, since 
fasting blood samples were not available from 39 patients. Patients 
with a triglyceride concentration >2.2 mmol/1 have a higher risk 
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Fig. 3. Systolic blood pressure and the progression of peripheral 
arterial disease. Progression of peripheral arterial disease has been 
assessed by reduction in anlde/brachial systolic index (ABPI). The 
number of patients entering each time interval is shown in 
parentheses. Patients in the middle tertile of blood pressure have the 
lowest risk of disease progression, p= 0.026. (-(3-) < 150mmHg; 
(--i--) 150-173mmHg; (-0-) > 174mmHg. 
Since most of the stoppers were recruited towards 
the end of the study a separate analysis was con- 
ducted for p.atients entering the study in 1988-1990. 
During this period 235 patients were entered, of 
whom 84 were stoppers and 151 were smokers. The 
median follow-up was 14.5 months for the stoppers 
and 18.3 months for the smokers. Again there was an 
increased proportion of diabetics in the stoppers 
(19/84, 23%) compared with the smokers (13/151, 
9%), p = 0.003. Hypertriglyceridaemia (> 2.2 mmoles/ 
1) was the only factor significantly associated with 
deterioration ofABPI, relative risk 1.77 (95% 1.06-2.95) 
p -- 0.029. 
Multivariate analysis 
Fasting blood samples were not available for 39 
patients. A multivariate analysis was performed to 
identify independent predictors of disease progression 
among the remaining 376 patients, using the following 
variables: age; sex; diabetes; pack-years; current smok- 
ing status; body mass index; presenting ABPI; ECG 
classification; systolic blood pressure; serum choles- 
terol and triglyceride concentrations. The only inde- 
pendent significant factor associated with deteriora- 
tion of ABPI was a triglyceride concentration of > 2.2 
mmol/1, which had a 1.8-fold increased risk [(9.5% CI 
1.23-2.59), p = 0.0026] compared with levels 
< 2.2mmol/1. 
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Development of critical ischaemia 
During the period of follow up 52 patients (12.5%) 
developed critical ischaemia 15 and required bypass 
surgery (Fig. 1). The risk of developing critical 
ischaemia increased 1.8-fold (95%CI 1.10-3.09) for 
patients presenting with ABPI of < 0.5, p = 0.016. The 
increased risk (1.7-fold) associated with a plasma 
triglyceride concentration of >2.2 mmol/1 was of 
borderline significance, p=0.057. Smoking, hyper- 
tension, diabetes, the presence of ischaemic heart 
disease and other factors were not associated with an 
altered risk of developing critical ischaemia nd the 
need for surgical intervention. However patients in 
the lowest age tertile ( < 61 years) had a 2-fold increase 
in risk of developing critical ischaemia, compared 
with those in the oldest tertile (> 69 years) p = 0.047. 
When the analysis was restricted to the 235 patients 
entering the study between 1988 and 1990 (84 stoppers 
and 151 smokers), hypertriglyceridaemia (__.2.2 
mmol/1) was the only significant factor associated 
with the onset of critical ischaemia, relative risk 2.31 
(95% CI, 1.09-4.87), p=0.024. Multiple regression 
analysis (376 patients with complete data set) identi- 
fied only young age and hypertriglyceridaemia as a 
significant predictor of the onset of critical ischaemia. 
Patients < 61 years had a 1.5-fold increase in risk (95% 
CI 1.10-2.32), p=0.03 and patients with a plasma 
triglyceride concentration had a 1.9 fold increase in 
risk (95% CI 1.08-2.87), p= 0.035. 
In 18 of the patients who developed critical ischae- 
mia (35%), the primary revascularization procedure 
failed and a secondary procedure was necessary. The 
relative risk of a secondary procedure increased 
lo7-fold for continuing smokers (15/18) and increased 
2.7-fold for those with a > 50 pack year history of 
smoking, Chi-squared, for trend 0.068. 
Discuss ion  
This study was established to investigate the short- 
term benefits of smoking cessation on intermittent 
claudication, and therefore only current smokers were 
enrolled in the study. All were counselled to stop 
smoking, but this counsel was only heeded by a 
minority. Two other features of the present study also 
contribute to its singularity among the studies of the 
prognosis and outcome of intermittent claudication: 
the use of objective markers of smoking and the 
measurement of change in ankle pressures, above the 
threshold for critical ischaemia. While the ankle/ 
brachial pressure index (ABPI) has a high specificity 
and sensitivity for the detection of peripheral arterial 
disease, the reliability and reproducibility of the ABPI 
has been questioned. 16Calcification of the peroneal 
and tibial vessels, as in diabetes or renal disease, can 
reduce the compressibility of these vessels resulting in 
falsely elevated ABPI valves. In our vascular labo- 
ratory the limits of agreement for repeated measure- 
ment of ABPI, over the range of 0.2-1.0, is + 0.14.14'17 
Therefore, our criterion for the progression of arterial 
disease was a reduction in ABPI of > 0.14. 
Smoking is a risk factor for most forms of cardiovas- 
cular disease, but is especially important for periph- 
eral arterial disease. 3 Cessation of smoking is asso- 
ciated with a decline in the risk of myocardial 
infarction in both men and women, but the increased 
risk attributable to smoking takes 5 or more years to 
disappear. 1s-2° Similarly the previous study of the 
influence of smoking cessation on the limb threatening 
complications of peripheral arterial disease only 
showed late benefits. 6 Seven years after the initial 
presentation with intermittent claudication, the cumu- 
lative rate of developing rest pain (critical ischaemia) 
was significantly higher in the continuing smokers, 
who contributed 83% of the patients. 6 In the short 
term (< 3 years) there was no difference in either 
survival or the risk of developing critical ischaemia. 6 
Our pilot studies had indicated that almost half the 
patients could be persuaded to stop smoking. The 
shock of a surgical consultation may facilitate the 
patient heeding the advice to "stop smoking and keep 
walking". 7 Using the smoking markers carboxyhae- 
moglobin and cotinine we observed that at the first 
follow-up visit almost half the patients (44%) 
appeared to have stopped smoking. Many of these 
had no symptomatic improvement and over sub- 
sequent follow-up there was a drift back to smoking 
and many patients were reclassified as smokers. This 
gradual return to smoking contributed to both the 
small proportion of stoppers (27%) and their short 
follow-up. In addition the last few years has seen a 
marked swing of public opinion against smoking, 
thereby providing an environment more conducive to 
cessation for those recruited later in the study. The 
shorter follow-up of stoppers, together with the 
increased proportion of diabetics in the stoppers and 
the tendency for stoppers to have higher systolic 
pressures and serum cholesterol concentrations than 
the smokers, are likely factors mitigating against our 
aim to show the shorter term (1-3 years) benefit of 
smoking cessation. In the short term (1-3 years), 
cessation of smoking did not appear to retard the 
progression of peripheral arterial disease. However, 
short term benefits of stopping smoking can be 
observed after vascular econstruction. In this study 
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only 52 patients underwent vascular econstruction 
for critical ischaemia, but even with this small number 
of patients there were clear trends for smoking to be 
associated with the failure of vascular econstruction, 
in keeping with previous tudies. 11'2~ 
The Framingham and other population-based stud- 
ies have shown that smoking, hypertension, diabetes, 
ischaemic heart disease and dyslipidaemia increase 
the risk of developing peripheral arterial disease. 2'22"2B 
In this study we have shown that only two of these 
risk factors, systolic blood pressure and dyslipidae- 
mia, are associated with the further progression of 
peripheral arterial disease. There was no significant 
association between serum cholesterol concentration 
and the progression of disease. However, patients 
with hypertriglyceridaemia (>2.2 mmol/1) had a 
significantly increased risk of disease progression 
compared with patients with lower triglyceride con- 
centrations. The association between hypertriglycer- 
idaemia and peripheral arterial disease has been 
recognised for many years, 24 although there is a 
debate as to whether this association is independent of 
HDL-cholesterol concentrations. 2B Hypertriglyceri- 
daemia is one of the features of the insulin resistance 
syndrome. 25'26 However, since we measured none of 
the other features of this syndrome including HDL- 
cholesterol, insulin concentration a d waist-hip ratio, 
we can only speculate as to whether hypertriglycer- 
idaemia was a marker for insulin resistance. 
The only other factor associated with the progres- 
sion of peripheral arterial disease, in the short term, 
was blood pressure. Some studies have demonstrated 
"U" or "J" shaped associations between blood pres- 
sure and risk of cardiovascular disease. 28 Systolic 
hypertension is recognised as a risk factor for the 
development of peripheral arterial disease. 2B Our 
finding that those in the middle fertile of systolic 
pressure had the lowest rate of disease progression is
consistent with this, since once disease is established 
an increased blood pressure is necessary to preserve 
limb perfusion. Even so, intermittent claudication may 
have an indolent course. After 3 years there was no 
evidence of disease progression in about half of the 
patients and less than one in seven patients had 
experienced the onset of critical ischaemia. This low 
rate of onset of critical ischaemia, over 3 years, in our 
study was similar to that observed by Jelnes et al. who 
observed that the rate of onset of critical ischaemia 
increases with time. 8 Even so, in our study the onset of 
critical ischaemia was faster in patients with hyper- 
triglyceridaemia. Our results also accord with several 
previous studies in showing that the risk of critical 
ischaemia was significantly higher when the present- 
ing ABPI was < 0.5. 8,9 
A recent study has indicated that fibrin degradation 
products and age predict outcome among those with 
intermittent claudication. 29 In contrast we observed 
that patients who presented at a younger age were at 
increased risk of developing critical ischaemia. This 
difference may be attributable to the different referral 
patterns in the two studies, but our previous experi- 
ence indicates that these younger patients have a more 
aggressive form of peripheral arterial disease. B°
In conclusion, the lack of short-term benefits of 
smoking cessation is likely to discourage patients with 
intermittent claudication from maintaining their 
resolve to stop smoking. Although this study has 
failed to demonstrate short erm (1-3 years) benefits of 
smoking cessation on the progression of peripheral 
arterial disease, it has reinforced the risks of smoking 
after vascular reconstruction and highlighted the 
potential risk of hypertriglyceridaemia to the progres- 
sion of peripheral arterial disease. 
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